Ultimately, the goal is not rapid or extreme weight loss but, rather, safe, sustainable, and medically meaningful improvements in health and quality of life
The safety and effectiveness of XIGDUO XR have not been established in pediatric patients to reduce the risk of [see Indications and Usage (1)]: sustained eGFR decline, end stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression
Long-term safety data still pending
Although these adverse events are generally similar to those seen with injectable formulations, they can become more prominent during dose escalation and titration periods
it is proven
An effective oral GLP-1 could challenge the current injectable market leaders and avoid supply chain issues